High Sensitivity Troponin T Levels Following DC Cardioversion for Atrial Fibrillation / Atrial Flutter

High Sensitivity Troponin T Levels Following Elective External Direct Current Cardioversion for Atrial Fibrillation / Atrial Flutter

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02268799

Enrollment

101

Registered

2014-10-20

Start date

2014-10-31

Completion date

2015-08-31

Last updated

2015-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Atrial Flutter

Keywords

Cardioversion, High Sensitivity Troponin T (Hs-Trop T), Brain Natriuretic Peptide (BNP), Neutrophil Gelatinase-associated Lipocalin (NGAL)

Brief summary

The purpose of this study is to determine if there is a rise in serum high sensitivity troponin T (a marker for heart muscle injury) following a direct current cardioversion (shock therapy) used for patients with atrial fibrillation. This will help us determine if direct current cardioversion results in damage to the heart muscles in a sufficient amount to cause a rise in high sensitivity troponin T.

Detailed description

High sensitivity Troponin T is a relatively new biomarker that is highly sensitive and specific for myocardial injury. Its widespread use has helped in the determination and investigation for myocardial ischemia in patients. Previous studies have shown a rise in creatine kinase (CK) and the more specific creatine kinase-MB isoenzyme (CKMB) after DC cardioversion. Studies on the earlier generation troponin T found that the levels don't rise or rise only minimally after DC cardioversion. The high sensitivity troponin T has never been studied in the setting of DC cardioversion.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with atrial fibrillation / atrial flutter attending for direct current external cardioversion * Age 18 or older

Exclusion criteria

* Myocardial infarction within the last 6 weeks * Coronary artery bypass grafting, percutaneous coronary intervention or any other invasive cardiac procedure within the last 6 weeks

Design outcomes

Primary

Measure	Time frame
High Sensitivity Troponin T levels pre and 6 hours post cardioversion	1 year

Secondary

Measure	Time frame
Creatine Kinase levels pre and 6 hours post cardioversion	1 year
B-type Natriuretic Peptide (BNP) levels pre and 6 hours post cardioversion	1 year
Neutrophil Gelatinase-associated Lipocalin (NGAL) levels pre and 6 hours post cardioversion	1 year

Countries

Ireland

Outcome results